AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Real-world Patient Experiences With Inbrija®

Recruitingn/aAges 18 Years - anyAllMerz Therapeutics GmbH
💬

In plain words

What the trial is, and whether it could suit you

Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing. This study aims to explore the experiences of people with Parkinson's disease who are prescribed Inbrija® as part of their usual care. Through a mixed-methods approach, the study will examine how OFF episodes affect patients, what influences their decision to use Inbrija®, and whether patient-reported outcomes related to symptoms, daily functioning, and quality of life change during the first 3 months of treatment. The study is planned to be conducted at approximately 7 sites in Austria, Germany, and Sweden and will enroll up to 120 participants receiving Inbrija® in routine clinical practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of Parkinson's disease with a history of OFF episodes. * Able and willing to provide informed consent. For the Quantitative Component: • Physician decision to initiate Inbrija® for the treatment of OFF episodes in Parkinson's disease according to routine clinical practice prior to enrollment. For the Qualitative Component: * Current user of Inbrija® for OFF episodes in Parkinson's disease according to approved prescribing conditions. * At least 6 weeks of regular Inbrija® use (minimum 4 uses during the previous month). * Able to participate in a 60-minute interview using an internet-enabled device. Exclusion Criteria: For the Quantitative Component: * Previous use of Inbrija® before study enrollment. * Participation in an interventional Parkinson's disease clinical trial within 3 months prior to Inbrija® initiation. * Residence outside Austria, Germany, or Sweden. * Current use of an on-demand treatment for OFF episodes other than Inbrija®. For the Qualitative Component: * Participation in an interventional Parkinson's disease clinical trial within 3 months prior to enrollment. * Residence outside Austria or Germany. * Current use of an on-demand treatment for OFF episodes other than Inbrija®.
💊

What it tests

  • Levodopa inhalation powder
📍

Where

2 sites
Neurologisches Therapiezentrum Gmundnerberg GmbH
Altmünster, Austria
Medizinischen Universität Graz
Graz, Austria
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy